N-acetyl Cysteine for Diabetic Eye Disease
Treatments studied
Part of Eyes & vision, Heart & circulation, Hormones & metabolism clinical trials.
This study tests whether a supplement called N-acetyl cysteine can help slow or improve mild to moderate diabetic eye disease (diabetic retinopathy). The goal is to see if it's safe and effective for people with type 2 diabetes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 2 diabetes with mild to moderate diabetic retinopathy (eye damage from diabetes)
- You are between 18 and 70 years old
- Your blood sugar control is reasonably good (HbA1C below 10%, fasting blood sugar below 240 mg/dL)
- You have not had eye surgery or laser treatment for your retinopathy
- You are not pregnant, breastfeeding, or using other antioxidant supplements
- Your liver and kidney function are normal or near-normal
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two types of diabetes medications (GLP-1 receptor agonists and SGLT2 inhibitors) to see how they affect blood vessels in the back of the eye over time. It may help doctors understand if one drug is better for protecting your eyes.
This study uses a special eye scan (OCTA) to look at the tiny blood vessels in the back of the eye and compares them between people with diabetes whose blood sugar is well-controlled and those whose is not. The goal is to understand how blood sugar control affects eye health in people with diabetic retinopathy.
This study tests a ginkgo biloba extract (EGb761) to see if it can help prevent or slow early diabetic retinopathy. Participants will receive the extract or a placebo (inactive pill), and their eye health will be monitored over time.
This Phase 2 study tests whether eye drops containing a medicine called N-acetylcysteine (NAC) can reduce damaging “reactive oxygen” in people with advanced Fuchs’ endothelial corneal dystrophy (FECD). It involves people who need a special cornea transplant (DMEK) at the same time as cataract surgery, aiming to improve cornea healing and vision.
This study tests whether an experimental eye drop can slow or treat early-stage diabetic retinopathy. If you have diabetes-related vision changes, this treatment might help prevent the condition from getting worse.
This study tests whether using a special eye scan (OCTA) to guide targeted laser treatment can slow down the progression of areas with poor blood flow in the retina of people with diabetic retinopathy. The goal is to prevent the condition from getting worse and help preserve your vision.
Hear when a new Diabetic Retinopathy (DR) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.